No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Dian Diagnostics Group Co.,Ltd. operates as a leading independent provider of medical diagnostic services within China. The company delivers comprehensive diagnostic solutions to a broad spectrum of healthcare organizations, including general and specialized hospitals, community health centers, township clinics, physical examination facilities, and disease prevention and control agencies. Supporting its extensive operations, Dian Diagnostics manages a global network of 40 advanced chain laboratories. Beyond its core diagnostic offerings, the company is also deeply involved in the research, development, and manufacturing of in vitro diagnostic reagents, along with associated equipment and consumables. Furthermore, it plays a crucial role in the medical supply chain, facilitating the provision of various products such as medical equipment, pharmaceuticals, clinical samples, biological products, finished blood products, live animals, chemical compounds, and diagnostic reagents. Dian Diagnostics also specializes in comprehensive cold chain logistics, which includes transportation, warehousing, product sales, and technical support services for temperature-sensitive medical goods. Founded in 2001, the company is headquartered in Hangzhou, China. It adopted its current name, Dian Diagnostics Group Co.,Ltd., in November 2017, having previously operated as Zhejiang DIAN Diagnostics Co., Ltd.
www.dazd.cnNo one on the platform currently holds 300244.SZ.
No tracked institution reports a position in 300244.SZ as of their last filing.
No one on the platform has traded 300244.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 1.3% | — | — | — | ||
| Rev. Growth % | -17.2% | -1.1% | ||||
| Profit Margin % | 0.4% | 3.2% | 4.7% | |||
| Free Cash Flow Margin % | 17.3% | 8.5% | 4.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $10.0B | -5.1% | $0.73 | $0.66–$0.86 | — | 2 |
| 2027 | $10.4B | +4.6% | $0.85 | $0.60–$1.11 | — | 4 |
| 2028 | $11.4B | +9.8% | $0.99 | $0.94–$1.06 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-20 | $0.24 | $0.27 | +12.5% |
| 2026-04-28 | $0.14 | $0.10 | -25.0% |
| 2026-04-22 | $-0.04 | $-0.02 | +48.3% |
| 2025-10-24 | $0.09 | $0.08 | -15.6% |
| 2025-08-20 | $0.08 | $0.05 | -37.5% |
| 2025-04-28 | $0.20 | $-0.03 | -115.0% |
| 2025-04-22 | $-0.33 | $-0.79 | -139.4% |
| 2024-10-23 | $0.16 | $0.10 | -37.5% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300244.SZDian Diagnostics Group Co.,Ltd. | $18.45 | +2.50% | $11.5B | — |
| 000503.SZChina Reform Health Management and Services Group Co., Ltd. | $6.66 | +0.00% | $6.5B | — |
| 002030.SZDaan Gene Co., Ltd. | $5.22 | +0.19% | $7.3B | — |
| 002099.SZZhejiang Hisoar Pharmaceutical Co., Ltd. | $5.36 | +0.00% | $8.7B | — |
| 300406.SZBeijing Strong Biotechnologies, Inc. |
| $11.15 |
| -0.54% |
| $6.5B |
| — |
| 300482.SZGuangzhou Wondfo Biotech Co.,Ltd | $15.63 | +0.51% | $7.3B | — |
| 300685.SZAmoy Diagnostics Co., Ltd. | $17.03 | +1.67% | $6.6B | — |
Source: Financial Modeling Prep · peers by sector/industry